ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BSEM / insiders
CVM (35) JSPR (36) PLUR (34) EVAX (46) ⌘ Pro Terminal β†’

BioStem Technologies Inc. (BSEM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.12 -13.18% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

BioStem Technologies Inc. (BSEM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $20.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BSEM Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BSEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, BioStem Technologies Inc. (NASDAQ: BSEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.12 (-13.18% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BSEM ranks #608 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BSEM compare to CVM and JSPR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BSEM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 93.6%, and ROIC of -5.7%. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $24.3M) and JSPR (Jasper Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $17.3M). Among the 5-stock peer group, BSEM leads on earnings multiple (N/A) while BSEM leads on capital efficiency (-5.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BSEM?
β–Ό

Per BSEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658678), BioStem Technologies Inc. generated $47.5M in revenue (-31.8% YoY), -$6.6M in net income, and $6.6M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.09 (-2.56%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 13.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (11)Whales (3)SEC (10)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$9 Bull$1 Base$1 Bear
πŸ“¬ FREE BSEM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BSEM)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY BSEM SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+11/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($6.6M FCF) & 93.6% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 2.44 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 5/9

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$2.25-27.1% Next Q
Q2 (-2Q)
40
Grade D$1.64-9.8% Next Q
Q3 (-1Q)
38
Grade E$1.48-24.3% Next Q
Current
35
Grade D-$1.12-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BSEM Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BSEM currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.98) and Max Pain ($1.18) forces dealer call-delta covering toward $8.82.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BSEMβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBSEM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BSEM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BSEM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BSEM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BSEM)

  • βœ“Walkthrough of BSEM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BSEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -74.55%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.29H $1.29L $1.12C $1.12VOL 145.6K
RES: $6.02SUP: $1.07SMA50: $2.98SMA200: $4.16
$5.95$4.64$3.32$2.01$0.70RES $6.02SUP $1.07$1.122026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BSEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BSEM Butterfly Map β†’ + Track BSEM β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BSEM today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BSEM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BSEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BSEM)

Health Care Rank #608 of 1015 βš”οΈ CVM vs BSEM Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BSEM vs. CVM, JSPR, PLUR, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BioStem Technologies Inc. (BSEM) ranks #608 by composite RQD confidence (35/100, grade D-) and #827 by equity capitalization ($20.9M). Within this direct 5-issuer industry benchmark cohort, BSEM leads on earnings valuation at N/A trailing P/E, while BSEM leads on capital efficiency and profitability with -5.7% ROIC and 93.6% gross margin. EVAX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BSEM at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BSEM ACTIVE
BioStem Technologies Inc.
D- 35/100 β€” 93.6% -5.7% -13.18% $20.9M Benchmark Subject
CVM
Cel-Sci Corporation
D- 35/100 β€” β€” -35.0% -8.00% $24.3M /cvm-vs-bsem β†’
JSPR
Jasper Therapeutics Inc.
D- 36/100 β€” β€” -35.0% -2.22% $17.3M /jspr-vs-bsem β†’
PLUR
Pluri Inc.
E 34/100 β€” 49.0% -35.0% +3.33% $16.7M /plur-vs-bsem β†’
EVAX
Evaxion A/S
D 46/100 β€” β€” β€” -4.87% $26.4M /evax-vs-bsem β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001658678 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioStem Technologies Inc. (BSEM) reported GAAP revenue of $47.5M (-31.8% vs. FY2024 revenue of $69.7M ) , GAAP net income of -$6.6M, operating cash flow of $9.9M, and free cash flow of $6.6M (-72.6% YoY). On the balance sheet, BSEM closed FY2025 with $50.0M in total assets against $0 in total debt (Altman Z-Score: 2.44, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $47.5M -$6.6M $9.9M $6.6M $50.0M β€”
FY2024 (FY) 2024-12-31 $69.7M $31.0M $24.5M $24.0M $58.3M β€”

3. BSEM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BSEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioStem Technologies Inc. (NASDAQ: BSEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.12 (-13.18% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BSEM ranks #608 in composite RQD confidence.

How does BSEM compare to CVM and JSPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BSEM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 93.6%, and ROIC of -5.7%. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $24.3M) and JSPR (Jasper Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $17.3M). Among the 5-stock peer group, BSEM leads on earnings multiple (N/A) while BSEM leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BSEM?

Per BSEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658678), BioStem Technologies Inc. generated $47.5M in revenue (-31.8% YoY), -$6.6M in net income, and $6.6M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BSEM trading relative to its 50-day, 200-day, and 52-week technical levels?

BSEM last traded at $1.12 (-13.18% on volume of 145,605 shares), positioning the stock -62.42% below its 50-day simple moving average ($2.98) and -73.08% below its 200-day simple moving average ($4.16). Across its 52-week range of $1.11 to $8.40, BSEM sits at the 0.1% percentile with a 14-day RSI of 26.0 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $1.26).

Direct Sub-Reports: BSEM RQD Cockpit BSEM 12M Forecast BSEM Earnings & Move BSEM Dividends & DRIP BSEM Insiders & 13F BSEM Whale Options BSEM Profit Sankey BSEM News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

BSEM β€” BioStem Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioStem Technologies Inc. (BSEM) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.12 (-13.18% 1D, market capitalization $20.9M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of -5.7%, gross margin of 93.6%, operating margin of -1.5%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.44, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioStem Technologies Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company reported revenue of $47.5M for FY 2025, down from $69.7M in FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioStem Technologies Inc. (BSEM) reported $47.5M in annual revenue (up from $69.7M in FY2024, -31.8% YoY) and -$6.6M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($69.7M revenue, $31.0M net income) through FY2025, BSEM scaled operating cash flow to $9.9M and free cash flow to $6.6M, backed by $50.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.11 – $8.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -1.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed from these sources.

  • Key Question #1: Can BSEM sustain or expand its -1.5% operating margin and -5.7% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $47.5M and free cash flow of $6.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BSEM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BSEM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioStem Technologies Inc. (BSEM) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BSEM Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BSEM Bull vs. Bear Conversation Board β€” What's Your Call at $1.12?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BSEM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BSEM:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $1.34 (+19.6%)
πŸ“Œ Pinned Debate

Insiders exercised options for shares at $2 each, reporting $1 million invested in cash, while the company held $29.5M in cash at FY 20

Long BSEM at $1.12 targeting $1.34. Insiders exercised options for shares at $2 each, reporting $1 million invested in cash, while the company held $29.5M in cash at FY 2025 end.. Institutional whale score is 3/20 and the risk/reward vs. the $1.11 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” BSEM's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.95 (-15.2%)
Spot @ $1.12

Net income fell from $31.0M in FY 2024 to -$6.6M in FY 2025, with ROIC at -5.7% and an RQD score of 35.

Here is the bear case nobody on the bull side wants to address on BSEM: Net income fell from $31.0M in FY 2024 to -$6.6M in FY 2025, with ROIC at -5.7% and an RQD score of 35.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%